# Fluticasone Furoate-Umeclidinium-Vilanterol

## Trelegy Ellipta 92/55/22 mcg Inhalation Powder

| 藥物代碼 | ETRE |
| :--- | :--- |
| 適應症 | Chronic obstructive pulmonary disease |
| 副作用 | 1% to 10%: Headache \(4%\), voice disorder \(&gt;=1%\), Diarrhea \(2%\), dysgeusia \(2%\), constipation \(&gt;=1%\), oral candidiasis \(&gt;=1%\), gastroenteritis \(1%\), Urinary tract infection \(&gt;=1%\), Influenza \(&gt;=1%\), Back pain \(4%\), arthralgia \(&gt;=1%\), Pneumonia \(8%\), bronchitis \(&gt;=1%\), pharyngitis \(&gt;=1%\), rhinitis \(&gt;=1%\), sinusitis \(&gt;=1%\), upper respiratory tract infection \(&gt;=1%\), cough \(1%\), oropharyngeal pain \(1%\)Frequency not defined:Paradoxical bronchospasm&lt;1%, postmarketing, and/or case reports: Anaphylaxis |
| 禁忌 | Hypersensitivity to fluticasone, umeclidinium, vilanterol, or any component of the formulation; severe hypersensitivity to milk proteins |
| 藥物保存方式 | 30度C以下 |
| 用法用量 | Oral inhalation: Dry powder inhaler: One inhalation \(fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg\) once daily \(maximum dose: 1 inhalation/day\) |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | \[仿單\] 只有再潛在效益超越beta作用劑干擾子宮收縮作用方面之可能風險的情況下, 才可於懷孕後期與分娩期間使用. FLUTICASONE PREGNANCY RECOMMENDATION: Compatible 其他成分無資料 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | [仿單](https://github.com/shin13/formulary-gitbook/tree/94da6e1290882bd3a20ba8b62cd5204e9fbdd50a/toc/re-00-00/re-04-00/節錄/README.md) 目前無人類資料,動物實驗資料Umeclidinium會進入乳汁. FLUTICASONE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible 其他成分無資料 |
| 注射劑給藥建議途徑 | INHL |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

